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This report is the last of a three-part series on the health of children and young people in New Zealand and fits 
into the reporting cycle as follows: 
Year 1 (2014): The determinants of health for children and young people  
Year 2 (2015): The health status of children and young people 
Year 3 (2016): The health of children and young people with chronic conditions and disabilities  
Chronic conditions and disabilities 
This report aims to assist district health boards to plan to meet current and future demands in order to improve 
the quality of life for children with disabilities and chronic conditions by providing: 
1. Information from a range of routinely collected data on children and young people’s disability and 
chronic conditions, including prevalence of conditions arising in the perinatal period 
2. Information about children’s and young people’s use of secondary health services 
3. Evidence for good practice derived from current policies, guidelines and evidence-based interventions 
for each of the indicators presented 
Chronic conditions and disabilities often affect people for life. Having a good quality of life and flourishing to 
your best ability is dependent, at least in part, on what happened as you were growing up. Understanding the 
dimensions of chronic conditions and disabilities among children and young people is essential to planning and 
developing good quality health services for New Zealand’s children and young people.  
About 11% of children aged 0–14 years have a disability according to the 2013 New Zealand Disability 
Survey.1 Of these children, the survey identified that 49% of children with impairments that limited daily 
activity were affected by conditions that existed at birth, while for a third of the children, the reason was one of 
a range of ‘other causes’, not usually diagnosed at birth, which include autism spectrum disorder, attention 
deficit hyperactivity disorder, developmental delay, dyslexia and dyspraxia. Learning difficulty was the most 
common impairment with 6% of children surveyed, and 52% of disabled children having difficulty learning. 
Boys had a disability rate of 13% compared with the girls’ rate of 8%, with boys having higher rates in 
psychiatric/psychological, speaking and learning impairments. Māori children had a disability rate of 15% 
compared with 9% for non-Māori children. Twenty five percent of disabled children had impairments that were 
caused by a disease or illness, and 3% by an injury.1  
The New Zealand Health Survey (NZHS) also indicates chronic conditions and disabilities that affect children 
and young people in New Zealand. The majority of 2–24 year olds have a BMI category of healthy weight, 
however, an estimated 11% prevalence of obesity was found among 2–14 year olds in the 2014/15 NZHS. This 
is of concern because there are implications for future health, given the association with type 2 diabetes and the 
risk of high blood pressure, coronary heart disease and stroke later in life.2 The unadjusted prevalence rate of 
childhood obesity in the 2014/15 NZHS was significantly higher than that in the 2006/07 survey. The rate for 
type 2 diabetes among 15–24 year olds is less than 1% and has been much the same in recent years. 
The prevalence of children being diagnosed with autism spectrum disorder varies with age, with the 2014/15 
NZHS rate being about 0.5% among those aged 2–4 years and 1.5% among the 10–14 year olds. Rates have 
increased over the years, reflecting similar trends overseas not fully understood but possibly influenced by 
increased recognition of the condition. 
The NZHS 2014/15 indicated that prevalence rates for eczema have been increasing, especially among those 
aged 0–4 years. Hospitalisations of 0–24 year olds has risen from below 100 to over 200 per 100,000 population 
for eczema and dermatitis as the primary diagnosis, while the rates rose from about 540 to 790 per 100,000 
population for cases where eczema and dermatitis were reported but were not the primary reason for the 
hospitalisation. These are often for the 0–4 year olds. The presence of such conditions for children and young 
people in hospital has implications for health services. 
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New indicators and new thinking have been taken into consideration in presenting data in this report. While 
obesity has traditionally been viewed as separate from eating disorders, increasingly they are being considered 
as parts of a continuum with common risk factors and scope for integrated prevention. Musculoskeletal 
conditions have been included reflecting an increasing rate of hospitalisations for the suite of conditions that 
includes juvenile arthritis, juvenile osteochondrosis, and scoliosis. 
A major limitation of this report is that it cannot address questions that require outpatient data. These data are 
not available at a national level. While the inclusion of the New Zealand Health Survey data provides a little 
more detail about estimated population prevalence for a few indicators, the full picture of outpatient and primary 
health care data is required for planning nationally and by district health boards.   
A further limitation in this report is the lack of data on the transition of children and young people into adult 
services, particularly in health, a process that those with chronic conditions and disabilities almost inevitably 
face. And a transition into adults able to reach their potential by achieving in education, gaining meaningful 
employment, and participating in their community is an aim that many children and young people with chronic 
conditions and disabilities aspire to.  
Review topics 
Two issues were selected by participating DHB for review and inclusion in this report: Fetal alcohol spectrum 
disorder (FASD) by Judith Adams, and the Health needs of children and young people in State care by Mavis 
Duncanson. 
Fetal alcohol spectrum disorder (FASD) contributes to many poor outcomes for New Zealand’s young people 
including early mortality, abuse and neglect, poor educational achievement, engagement with the criminal 
justice system, benefit dependence, and mental health and alcohol and drug problems. This chapter provides 
information on the features of FASD, the life course consequences of FASD and the comorbidities of FASD. It 
discusses international studies on the epidemiology of FASD. Diagnosis of FASD is not straightforward 
therefore methods of diagnosis are reviewed along with the findings from a review of the Hawke’s Bay DHB’s 
FASD assessment pathway. Subsequent sections look at the evidence base for interventions to address the 
difficulties faced by people with FASD and their families. The final sections review what is known about 
New Zealand women’s drinking habits, the patterns of drinking that are associated with the greatest risk of 
FASD and the evidence regarding the effectiveness of interventions to prevent the harm resulting from prenatal 
exposure to alcohol. 
In New Zealand there have consistently been around 5,000 children and young people in the custody of the 
Chief Executive of Child, Youth and Family (in CYF care) each year. Many children and young people referred 
to Child, Youth and Family have high levels of long-term need and disadvantage. Health and educational 
assessments (Gateway Assessments) of children and young people in CYF care have identified multiple health 
needs for most children. Internationally it is well recognised that children and young people in State care often 
present with complex and serious health problems. This chapter uses published reports to describe the group of 
children in CYF care in New Zealand and to outline key characteristics of the current and proposed new care 
and protection systems, particularly those relevant to health services. The chapter also provides a rapid review 
of New Zealand and international literature regarding the health needs of children and young people in State 
care and guidelines for best practice in providing care to them.  
In addition, the content of the appendices may be helpful when interpreting information in this report.  
Appendix 1 provides an overview of the methods used to develop the reviews of evidence for good practice 
which appear at the conclusion of most indicator chapters. Appendix 2 describes the statistical methods used, 
including a description of rates calculated within the data. Appendix 3. Data sourcescontains information on the 
data sources used to develop each indicator and discusses data limitations. Appendix 4. Demographic 
factorsdeals with the measurement of ethnicity and also provides an overview of the NZ Deprivation Index; 
NZDep 2013 is used where data relate to the 2013 Census. Appendix 5 displays the tables of clinical codes 
referred to in this report.  
Conclusion 
This report reviews the prevalence of a range of disabilities and chronic conditions experienced by children and 
young people living in New Zealand. These conditions place demands on health and disability support services 
needed to provide. This report provides information on the secondary health service utilisation patterns of 
children and young people with chronic conditions and disabilities. It is unable to provide data on all health 
service use as these data are not collated nationally. It does, however, aim to provide some insights into two 
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quite different perspectives of disability and chronic conditions: the consequences and management of children 
with fetal alcohol syndrome, and a review of the health needs of children in care. 
While the data presented are at times imperfect, and at best only provide a glimpse of the health needs of these 
diverse groups of children and young people, the current paucity of data should not preclude DHBs reviewing 
the health and disability support services available locally (including those with a public health focus), with a 
view to considering whether further improvements are required within the region. 
Increasingly high quality evidence is becoming available to direct future initiatives for a number of the 
conditions included here. The number of systematic reviews has risen exponentially in many of these fields. 
Some of these will inform the development of integrated services to benefit the children and young people with 
chronic conditions and disabilities, and those who care for them. 
Table 1 to Table 3 present an overview of children and young people in the Southern DHB hospitalised with 
chronic conditions between 2011 and 2015, babies born with congenital anomalies and babies who died as a 
result of congenital anomalies between 2009 and 2013, and cancer notifications of children and young people 
between 2010 and 2014. Congenital anomaly rates are per 1,000 total births and cancer notification rates are age 
standardised rates per 100,000 population. Details for indicators with small numbers are suppressed. New 
Zealand data are presented for comparison.  
Table 1. Summary of data for 0–24 year olds with chronic conditions Southern DHB vs. New Zealand 
Indicator 















Cystic fibrosis 27 167 200 
 336 2122 2625 
Diabetes 338 743 1187  4137 6466 12308 
Eating disorders 105 144 221  1012 1509 2301 
Autism spectrum disorder 91 34 180  1853 485 3015 
Cerebral palsy 103 62 340  1678 2458 5852 
Epilepsy 275 505 662  4336 7440 9876 
Chronic lower respiratory diseases 1488 2038 2503  29184 37909 48433 
Inflammatory bowel disease 136 422 534  1447 5168 5999 
Constipation 1109 778 1504  14578 7805 18723 
Eczema and dermatitis 903 264 1100  15331 5022 18950 
Musculoskeletal disorders 113 123 167  1506 2431 3016 
            
  n DHB 
rate 
95% CI  n NZ rate 95% CI 
Babies with one or more congenital 
anomalies 
1242 67.41 63.71–71.26 
  
21219 67.56 66.66–68.48 
Infant mortality with congenital 
anomalies 
18 0.98 0.58–1.55 
  
439 1.41 1.28–1.55 
Cancer notifications 0–14 year olds 41 14.67 10.53–19.91   699 14.67 10.53–19.91 
Cancer notifications 15–24 year olds 47 19.89 14.61–26.45   821 26.34 24.57–28.21 
Unique individuals* were identified as being hospitalised at least once from 2011–2015; †all relevant hospitalisations 2011–2015 
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Table 2. Summary of data for 0–24 year olds with chronic conditions Otago area vs. New Zealand 
Indicator 













Cystic fibrosis 19 128 149 
 336 2122 2625 
Diabetes 214 416 720  4137 6466 12308 
Eating disorders 88 125 190  1012 1509 2301 
Autism spectrum disorder 70 17 137  1853 485 3015 
Cerebral palsy 68 38 240  1678 2458 5852 
Epilepsy 167 288 381  4336 7440 9876 
Chronic lower respiratory diseases 822 964 1232  29184 37909 48433 
Inflammatory bowel disease 97 295 374  1447 5168 5999 
Constipation 716 517 1010  14578 7805 18723 
Eczema and dermatitis 560 144 660  15331 5022 18950 
Musculoskeletal disorders 74 74 108  1506 2431 3016 
            
  n Region 
rate 
95% CI  n NZ rate 95% CI 
Babies with one or more congenital 
anomalies 
753 72.49 67.41–77.86 
  
21219 67.56 66.66–68.48 
Infant mortality with congenital 
anomalies 
11 1.07 0.53–1.91 
  
439 1.41 1.28–1.55 
Cancer notifications 0–14 year olds 28 17.12 10.74–23.38   699 14.67 10.53–19.91 
Cancer notifications 15–24 year olds 29 17.58 11.18–23.98   821 26.34 24.57–28.21 
Unique individuals* were identified as being hospitalised at least once from 2011–2015; †all relevant hospitalisations 2011–2015 
Table 3. Summary of data for 0–24 year olds with chronic conditions Southland area vs. New Zealand 
Indicator 









All cases  Primary 
diagnosis 
All cases 
Cystic fibrosis 9 39 51  336 2122 2625 
Diabetes 133 327 467  4137 6466 12308 
Eating disorders 17 19 31  1012 1509 2301 
Autism spectrum disorder 24 17 43  1853 485 3015 
Cerebral palsy 37 24 100  1678 2458 5852 
Epilepsy 110 217 281  4336 7440 9876 
Chronic lower respiratory diseases 672 1074 1271  29184 37909 48433 
Inflammatory bowel disease 43 127 160  1447 5168 5999 
Constipation 398 261 494  14578 7805 18723 
Eczema and dermatitis 346 120 440  15331 5022 18950 
Musculoskeletal disorders 40 49 59  1506 2431 3016 
            
  n Region rate 95% CI  n NZ rate 95% CI 
Babies with one or more congenital 
anomalies 
489 60.84 55.56–66.48   21219 67.56 66.66–68.48 
Infant mortality with congenital 
anomalies 
7 0.88 0.35–1.81   439 1.41 1.28–1.55 
Cancer notifications 0–14 year olds 13 11.21 5.11–17.29   699 14.67 10.53–19.91 
Cancer notifications 15–24 year olds 18 25.23 13.56–36.86   821 26.34 24.57–28.21 
Unique individuals* were identified as being hospitalised at least once from 2011–2015; †all relevant hospitalisations 2011–2015 
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Congenital anomalies, also known as birth defects, congenital disorders or congenital malformations, are 
structural or functional anomalies that exist at or before birth (although they may not be detected until later in 
life).1 They are major causes of fetal, infant and child deaths, and chronic illness and disability.1 Congenital 
anomalies may occur in isolation or they may occur together in a pattern corresponding to a named syndrome, 
such as Down syndrome or achondroplasia (dwarfism).2 
Congenital anomalies vary in severity from the inevitably lethal, such as absent kidneys, to minor abnormalities 
of cosmetic significance only. Major anomalies, those anomalies that have medical and/or social implications 
and often require surgical repair, occur in approximately three to four percent of all live births.3 Common major 
anomalies include heart defects, cleft lip and palate, neural tube defects, and chromosomal abnormalities (the 
most common of which is Down syndrome).3 
In at least half of all occurrences of congenital anomaly, no cause can be identified.1,4 Genetic factors are 
important in many congenital anomalies, particularly syndromic anomalies.1 Genetic factors cause around one 
third of all congenital anomalies and about 85% of those with known causes.5 Environmental factors of various 
kinds can cause congenital anomalies, for example: insufficient maternal intake of folic acid increases the risk of 
neutral tube defects; maternal infection with Zika virus seems to cause microcephaly; and poorly controlled 
pregestational maternal diabetes increases the risk of major anomalies in the cardiovascular and central nervous 
systems and in craniofacial structures.1,6 
The following section uses data from the National Minimum Dataset to describe congenital anomalies in babies 
from 2000–2015 and concludes with a brief overview of some of the evidence relating to early diagnosis of 
these conditions. 
Data sources and methods 
Indicators  
 
Prevalence of congenital anomalies 
Infant mortality associated with congenital anomalies 
Definition  
Anomalies diagnosed in stillbirths and liveborn babies up to one year of age are included, and cases identified based on codes 
adapted from those used by BINOCAR and by registers in Australia7 
Stillbirths are of at least 400g birthweight or 20 weeks gestation (as defined by the Ministry of Health) 
Numerators: Liveborn infants hospitalised: National Minimum Dataset 
 Stillbirths: National Mortality Collection 
 Infant deaths associated with congenital anomalies: National Mortality Collection 
Denominators:  Total births 
 
Livebirths: Birth Registration Dataset 
Stillbirths: National Mortality Collection 
Prevalence per 1,000 livebirths 
Additional information 
Anomalies are year of birth; births are registration year. 
Codes used for identifying cases are documented in Appendix 5. Clinical codesError! Reference source not found. 
Maternal age was only available for 72% of cases. 
Prevalence rates presented for sex-specific anomalies are sex-specific rates. 
The confidence intervals are calculated using the Poisson distribution. 
National trends and distribution 
The infant mortality rate in New Zealand between 2009 and 2013 was 5.14 per 1,000 live births. Over 27% of 
the infants who died had at least one congenital anomaly (Table 4). The infant mortality rate associated with 
congenital anomalies gradually decreased from 1990–91 to 2006–07 and from then on increased slightly from 
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year to year (Figure 1). Congenital heart defects, nervous system defects, and chromosomal anomalies were the 
predominant congenital anomaly subgroups contributing to infant mortality (Table 4).  
Table 4. Infant mortality with one or more congenital anomalies, by anomaly subgroup, New Zealand 2009–2013 
2009–2013 n 
Rate per 1,000 
livebirths 
95% CI 
Congenital anomaly infant mortality 
New Zealand 
Infant mortality 1,603 5.14 4.89–5.40 
Infant mortality with a congenital anomaly* 439 1.41 1.28–1.55 
Congenital heart defects 181 0.58 0.50–0.67 
Nervous system 82 0.26 0.21–0.33 
Chromosomal anomalies 79 0.25 0.20–0.32 
Digestive system 64 0.21 0.16–0.26 
Urinary 54 0.17 0.13–0.23 
Respiratory 48 0.15 0.11–0.20 
Neural tube defects 33 0.11 0.07–0.15 
Limb 20 0.06 0.04–0.10 
Abdominal wall defects 11 0.04 0.02–0.06 
Eye <10 s s 
Orofacial clefts <10 s s 
Genital <10 s s 
Ear, Face and Neck 0 .. .. 
Numerator: National Mortality Collection, Denominator: Birth registration data. Congenital anomaly infant mortality per 
1,000 livebirths. *Infant mortality with one or more anomalies. One infant excluded for presence of single anomaly of minor 
severity; Some Infant mortality will have multiple anomalies and appear in more than one subgroup 
Figure 1. Infant mortality with one or more congenital anomalies, by year, New Zealand 1990–2013 
 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Babies with one or more diagnosed 
anomalies 
The number of babies with at least one congenital anomaly (including minor defects) gradually increased from 
2000 to 2007. There was a noticeable dip between 2008 and 2011 which corresponded with a decrease in 
diagnoses of minor skin anomalies, such as tags and birth marks. From 2012 onwards numbers have been 
similar to those in 2007 (Figure 2). The proportion of babies born with one or more congenital anomalies has 














































































































































Figure 2. Number of babies born and those with one or more congenital anomalies, by year, New Zealand 
2000-2015 
 
Source: National Minimum Dataset, National Mortality Collection, Birth registration dataset. (Total) births corresponds to live 
births and fetal deaths, * = 2014 and 2015 are live births only 
Table 5. Proportion of babies with one or more congenital anomalies, by year, New Zealand 2000–2015 
Year Babies with an anomaly (n) Total births (n) % of total births 
New Zealand 
Congenital anomalies 
2000–2008 39,291 536,368 7.3 
2009 3,744 63,767 5.9 
2010 4,004 65,168 6.1 
2011 3,991 62,624 6.4 
2012 4,650 62,483 7.4 
2013 4,830 60,026 8.0 
2014* 4,971 58,285 8.5 
2015* 4,535 62,122 7.3 
Total 70,016 970,843 7.2 
Source: National Minimum Dataset, National Mortality Collection, Birth registration dataset. Total births corresponds to live 
births and fetal deaths, 2014 and 2015 are live births only 
Diagnosis  
Table 6 presents the number of cases and prevalence for each congenital anomaly subgroup. The group of 
anomalies with the highest prevalence between 2009 and 2013 was digestive system anomalies, followed by 
congenital heart defects, and then limb anomalies. Refer to Appendix 5. Clinical codes for details on the 
































































































































Table 6. Babies with one or more congenital anomalies, by anomaly subgroup, New Zealand 2009–2013 
Babies with an anomaly (n) 





All cases** 21,219 67.56 66.66–68.48 
Digestive system 7,075 22.53 22.01–23.06 
Congenital heart defects 3,902 12.42 12.04–12.82 
Limb 3,536 11.26 10.89–11.64 
Genital 2,140 6.81 6.53–7.11 
Urinary 1,322 4.21 3.99–4.44 
Respiratory 1,186 3.78 3.56–4.00 
Nervous system 748 2.38 2.21–2.56 
Chromosomal anomalies 701 2.23 2.07–2.40 
Ear, Face and Neck 689 2.19 2.03–2.36 
Orofacial clefts 524 1.67 1.53–1.82 
Eye 233 0.74 0.65–0.84 
Abdominal wall defects 228 0.73 0.63–0.83 
Neural tube defects 150 0.48 0.40–0.56 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly, Babies are counted once overall, once for each sub-group and 
for each anomaly documented; ** all cases 
Demographic distribution 
Table 7 presents the demographic distribution of congenital anomalies in New Zealand between 2009 and 2013. 
There were no significant differences by New Zealand Deprivation Index quintile. The prevalence of anomalies 
was significantly higher for male babies. Māori, Pacific, Asian/Indian and MELAA babies all had statistically 
significantly lower congenital anomaly prevalence rates than babies of European/Other ethnicities but only the 
Māori rate was markedly lower than the European/Other rate. Compared to babies born to mothers aged 30–34 
years, babies born to mothers aged 20–29 years had slightly but significantly lower rates while babies born to 
mothers aged over 35 years had significantly higher rates. Over the period 2000–2015, rates for the four largest 
ethnic groups were reasonably steady although there was a dip in rates between 2006 and 2012 (Figure 3). 
Rates for Māori babies were consistently considerably lower than rates for other babies (Figure 3).  
Figure 3. Babies with one or more congenital anomalies, by ethnicity, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. (Total) births corresponds to live births and fetal deaths, 2014 and 2015 are live births only. Babies with one 




































Table 7. Babies with one or more congenital anomalies, by demographic factor, New Zealand 2009–2013 
Variable 2009–2013 (n) 
Prevalence per 
1,000 births 
Rate ratio 95% CI 
Congenital anomalies 
NZ Deprivation Index quintile 
Deciles 1–2 3,088 67.77 1.00   
Deciles 3–4 3,430 68.06 1.00 0.96–1.05 
Deciles 5–6 3,731 64.79 0.96 0.91–1.00 
Deciles 7–8 4,737 68.61 1.01 0.97–1.06 
Deciles 9–10 6,168 68.35 1.01 0.97–1.05 
Prioritised ethnicity  
Māori 4,353 47.76 0.61 0.59–0.63 
Pacific 2,445 69.47 0.89 0.85–0.93 
Asian/Indian 2,865 72.82 0.93 0.90–0.97 
MELAA 343 64.29 0.82 0.74–0.91 
European/Other 11,144 77.97 1.00   
Gender 
Female 8,442 55.20 1.00   
Male 12,773 79.28 1.44 1.40–1.47 
Maternal age 
<20 years 996 48.55 1.00 0.93–1.06 
20–24 years 2,526 43.52 0.89 0.85–0.94 
25–29 years 3,554 45.02 0.92 0.88–0.96 
30–34 years 4,291 48.79 1.00   
35+ years 3,860 56.26 1.15 1.11–1.20 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly, Rate ratios are unadjusted, Ethnicity is level 1 prioritised, 
Decile is NZDep2013, Maternal age reported where available 
Maternal age 
The lowest prevalence rate of congenital anomalies between 2009 and 2013 was for babies born to mothers aged 
20–24 years at delivery. Prevalence was significantly lower for babies born to mothers aged 20–29 years and 
significantly higher for babies born to mothers 35 years and over (compared to mothers aged 30–34 years; 
Table 7, Table 8). The prevalence of chromosomal anomalies increased with increasing maternal age with the 
highest prevalence being for babies born to mothers aged 35 years and over. Prevalence of non-chromosomal 
anomalies was highest for babies born to mothers aged under 20 years and 35 years and over (U-shaped 
distribution across the maternal age groups). Most of the non-chromosomal anomaly subgroups had a U-shaped 
prevalence distribution except for abdominal defects, for which the prevalence was highest for the under 20 year 
maternal age group and decreased as maternal age increased (Table 8). 
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Total <20 years 20–24 years 25–29 years 30–34 years 35+ years 
Congenital anomalies 
New Zealand 
Total births (n) 314,068 20,513 58,042 78,941 87,956 68,616 
Babies with an 
anomaly (n) 
21,219 996 2,526 3,554 4,291 3,860 





























































































































































Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. **Babies are counted once overall, some babies will have multiple anomalies and appear in more than one 
row, Maternal age reported where available. * Non-chromosomal anomalies exclude cases with chromosomal anomalies 
present, NS = Nervous system, CHD = Congenital heart defects, OFC = Oro-facial clefts, Abdominal = Abdominal wall defects 
Regional trends and distribution 
The proportion of infant deaths with at least one congenital anomaly between 2009 and 2013 was 25.4% in 
Southern DHB (Table 9). The congenital anomaly infant mortality rate in Southern DHB was not significant 
different from the national rate between 2009 and 2013 (Figure 4, Table 9).  
There has been considerable year-on-year variability in the infant mortality rate associated with congenital 
anomalies in Southern DHB since 1990–91. Rates in Southland have gradually decreased while been highly 
variable in Otago (Figure 5). 
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Figure 4. Infant mortality with one or more congenital anomalies, by district health board, New Zealand 
2009– 2013 
 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Infant mortality with one or more diagnosed 
anomalies (excludes select minor anomalies); Congenital anomaly infant mortality per 1,000 livebirths 
Table 9. Infant mortality with one or more congenital anomalies, by district health board, Southern DHB vs 
New Zealand 2009–2013 
2009–2013 
Infant mortality 
with an anomaly (n) 
Rate Rate ratio 95% CI 
% of infant 
deaths 
Congenital anomaly associated infant mortality 
Southern DHB 18 0.98 0.70 0.44–1.12 25.4 
Otago 11 1.07 0.76 0.42–1.38 28.9 
Southland 7 0.88 0.62 0.30–1.31 21.2 
New Zealand 439 1.41 1.00   27.4 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Infant mortality with one or more diagnosed 
anomalies (excludes select minor anomalies); Congenital anomaly infant mortality per 1,000 livebirths 
Figure 5. Infant mortality with one or more congenital anomalies, by year, Southern DHB vs New Zealand 
1990– 2013 
 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Babies with one or more diagnosed 











































































































































































































































































































































































































































































































































































The prevalence of babies with a congenital anomaly was not significantly different than the national rate 
between 2009 and 2013 in Southern DHB (Figure 6, Table 10).  
The prevalence of babies with at least one congenital anomaly has gradually decreased since 2000 in Southern 
DHB. Prevalence rates were generally higher than the national rate (Figure 7).  
Figure 6. Babies with one or more congenital anomalies, by district health board, New Zealand 2009–2013 
 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. (Total) births corresponds to live births and fetal death; Babies with one or more diagnosed anomalies 
(excludes select minor anomalies) 
Table 10. Babies with one or more congenital anomalies, by district health board, Southern DHB vs New Zealand 
2009–2013 
Babies with an anomaly 2009–2013 (n) Rate per 1,000 births Rate ratio 95% CI 
Congenital anomalies 
Southern DHB 1,242 67.41 1.00 0.94–1.05 
Otago 753 72.49 1.07 1.00–1.15 
Southland 489 60.84 0.90 0.83–0.98 
New Zealand 21,219 67.56 1.00   
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Prevalence per 1,000 births; (Total) births corresponds to live births and fetal death; Babies with one or 















































































































































































































Figure 7. Babies with one or more congenital anomalies, by year, Southern DHB vs New Zealand 2000–2015 
 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration data and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); (Total) births corresponds 
to live births and fetal deaths, * 2014 and 2015 are live births only 
Diagnosis  
The number of babies with at least one congenital anomaly diagnosed before the age of one year between 2009 
and 2013 and prevalence for each congenital anomaly subgroup are presented for Southern DHB in Table 11. 
The anomaly subgroups with the highest prevalence rates were congenital heart defects, limb and urinary system 
anomalies. Regional information for Otago and Southland is also presented (Table 12, Table 13).   
Table 11. Babies with one or more congenital anomalies, by anomaly subgroup, Southern DHB 2009–2013 
  2009–2013 (n) 





All cases** 1,242 67.41 63.71–71.26 
Nervous system 36 1.95 1.37–2.71 
Neural tube defects <10 s s 
Eye 17 0.92 0.54–1.48 
Ear, Face and Neck 22 1.19 0.75–1.81 
Congenital heart defects 309 16.77 14.95–18.75 
Respiratory 73 3.96 3.11–4.98 
Orofacial clefts 30 1.63 1.10–2.32 
Abdominal wall defects 13 0.71 0.38–1.21 
Digestive system 442 23.99 21.80–26.33 
Urinary 118 6.40 5.30–7.67 
Genital 67 3.64 2.82–4.62 
Limb 168 9.12 7.79–10.61 
Chromosomal anomalies 36 1.95 1.37–2.71 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Babies are counted once 






































































































































































































































Table 12. Babies with one or more congenital anomalies, by anomaly subgroup, Otago area of Southern DHB 
2009–2013 
  2009–2013 (n) 





All cases** 753 72.49 67.41–77.86 
Nervous system 20 1.93 1.18–2.97 
Neural tube defects <10 s s 
Eye <10 s s 
Ear, Face and Neck 11 1.06 0.53–1.90 
Congenital heart defects 195 18.77 16.23–21.60 
Respiratory 43 4.14 3.00–5.58 
Orofacial clefts 18 1.73 1.03–2.74 
Abdominal wall defects <10 s s 
Digestive system 346 33.31 29.89–37.01 
Urinary 34 3.27 2.27–4.57 
Genital 31 2.98 2.03–4.24 
Limb 78 7.51 5.94–9.37 
Chromosomal anomalies 25 2.41 1.56–3.55 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Babies are counted once 
overall, once for each sub-group and for each anomaly documented 
Table 13. Babies with one or more congenital anomalies, by anomaly subgroup, Southland area of Southern DHB 
2009–2013 
  2009–2013 (n) 





All cases** 489 60.84 55.56–66.48 
Nervous system 16 1.99 1.14–3.23 
Neural tube defects <10 s s 
Eye <10 s s 
Ear, Face and Neck 11 1.37 0.68–2.45 
Congenital heart defects 114 14.18 11.70–17.04 
Respiratory 30 3.73 2.52–5.33 
Orofacial clefts 12 1.49 0.77–2.61 
Abdominal wall defects <10 s s 
Digestive system 96 11.94 9.67–14.58 
Urinary 84 10.45 8.34–12.94 
Genital 36 4.48 3.14–6.20 
Limb 90 11.20 9.00–13.76 
Chromosomal anomalies 11 1.37 0.68–2.45 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Babies are counted once 
overall, once for each sub-group and for each anomaly documented 
Demographic distribution 
Table 14 to Table 16 present the demographic distribution of babies with at least one congenital anomaly for 
Southern DHB and its regions between 2009 and 2013.  
The prevalence of anomalies was significantly higher for male babies, and among babies residing in areas with 
high deprivation scores (NZDep2013 deciles 7–10) in Southern DHB. Māori and Asian/Indian babies had 
significantly lower congenital anomaly prevalence rates than babies of European/Other ethnicities.   
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The lowest prevalence rate of congenital anomalies between 2009 and 2013 in Southern DHB were for babies 
born to mothers aged 25–29 years at delivery. Prevalence was higher for babies born to mothers aged 35 years 
and over (compared to mothers aged 30–34 years), although this difference was not significant.  
Table 14. Babies with one or more congenital anomalies, by demographic factor, Southern DHB 2009–2013 
Variable n Rate 
Rate 
ratio 






NZ Deprivation Index quintile Prioritised ethnicity  
Deciles 1–2 250 55.58 1.00   Māori 137 37.30 0.49 0.41–0.58 
Deciles 3–4 263 65.80 1.18 1.00–1.40 Pacific 45 69.44 0.91 0.68–1.22 
Deciles 5–6 298 69.40 1.25 1.06–1.47 Asian/Indian 50 54.23 0.71 0.54–0.94 
Deciles 7–8 281 77.77 1.40 1.19–1.65 MELAA 19 71.70 0.94 0.61–1.46 
Deciles 9–10 148 73.16 1.32 1.08–1.60 European/Other 981 76.01 1.00   
Maternal age Gender 
<20 years 42 42.64 0.86 0.62–1.18 Female 517 58.24 1.00   
20–24 years 132 42.48 0.85 0.70–1.05 Male 725 75.93 1.30 1.17–1.45 
25–29 years 211 43.70 0.88 0.74–1.05 
  30–34 years 277 49.71 1.00   
35+ years 243 61.78 1.24 1.05–1.47 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Rate per 1,000 births; Rate 
ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013; Maternal age reported where available 
In the Otago region of Southern DHB, the prevalence of anomalies was significantly higher among babies 
residing in areas with moderate deprivation scores (NZDep2013 deciles 3–8). There was no significant 
difference by sex or maternal age. Māori and Asian/Indian babies had significantly lower congenital anomaly 
prevalence rates than babies of European/Other ethnicities (Table 15).   
In Southland, prevalence was significantly higher for male babies, among babies residing in areas with high 
deprivation scores (NZDep2013 deciles 7–10), and significantly lower for Māori babies (compared with babies 
of European/Other ethnicities), or babies born to mothers aged 25–29 years at delivery (Table 16).  
Table 15. Babies with one or more congenital anomalies, by demographic factor, Otago area of Southern DHB 
2009–2013 
Variable n Rate 
Rate 
ratio 






NZ Deprivation Index quintile Prioritised ethnicity  
Deciles 1–2 145 61.83 1.00   Māori 66 35.62 0.44 0.34–0.56 
Deciles 3–4 161 73.58 1.19 0.96–1.48 Pacific 28 67.80 0.83 0.58–1.20 
Deciles 5–6 233 76.42 1.24 1.01–1.51 Asian/Indian 32 60.61 0.74 0.53–1.05 
Deciles 7–8 185 81.28 1.31 1.07–1.62 MELAA 10 68.49 0.84 0.46–1.53 
Deciles 9–10 29 54.82 0.89 0.60–1.31 European/Other 607 81.60 1.00   
Maternal age Gender 
<20 years 19 40.51 0.77 0.48–1.22 Female 327 64.79 1.00   
20–24 years 73 44.43 0.84 0.64–1.10 Male 426 79.78 1.23 1.07–1.41 
25–29 years 140 52.85 1.00 0.81–1.24 
  30–34 years 172 52.74 1.00   
35+ years 167 70.61 1.34 1.09–1.65 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Rate per 1,000 births; Rate 
ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013; Maternal age reported where available 
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Table 16. Babies with one or more congenital anomalies, by demographic factor, Southland area of Southern DHB 
2009–2013 
Variable n Rate 
Rate 
ratio 






NZ Deprivation Index quintile Prioritised ethnicity  
Deciles 1–2 105 48.77 1.00   Māori 71 39.01 0.57 0.45–0.73 
Deciles 3–4 102 56.38 1.16 0.89–1.51 Pacific 17 72.34 1.06 0.66–1.69 
Deciles 5–6 65 52.21 1.07 0.79–1.45 Asian/Indian 18 45.69 0.67 0.42–1.06 
Deciles 7–8 96 71.80 1.47 1.13–1.93 MELAA 9 75.63 1.11 0.59–2.09 
Deciles 9–10 119 79.65 1.63 1.27–2.11 European/Other 374 68.40 1.00   
Maternal age Gender 
<20 years 23 44.57 0.98 0.63–1.52 Female 190 49.61 1.00   
20–24 years 59 40.30 0.89 0.65–1.21 Male 299 71.06 1.43 1.20–1.71 
25–29 years 71 32.58 0.72 0.53–0.96 
  30–34 years 105 45.43 1.00   
35+ years 76 48.47 1.07 0.80–1.42 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly (excludes select minor anomalies); Rate per 1,000 births; Rate 
ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013; Maternal age reported where available 
Evidence for good practice 
Possibilities for prevention 
The majority of congenital malformation have no known cause. For this reason, the avenues for prevention are 
limited and the effects of interventions modest. Some major structural malformations can be detected during 
pregnancy via ultrasound examination, and most chromosomal and some genetic disorders can be detected via 
amniocentesis or chorionic villus sampling. Prenatal diagnosis allows parents to choose termination when their 
fetus has a condition likely to be fatal or severely disabling, and delivery in a tertiary centre with appropriate 
surgical expertise when their baby will require surgery soon after birth. 
Table 17 indicates where prenatal detection is possible (to a variable degree), by ultrasound examination and/or 
genetic testing, where optimal health status before and during pregnancy and good antenatal care may reduce the 
incidence of the condition, and where early postnatal detection improves outcomes. For genetic conditions 
(including cystic fibrosis) pre-natal genetic testing is generally offered only in cases where there is a family 
history of the condition or where a genetic condition is suspected, for example, as a result of findings from 
maternal blood tests and/or prenatal ultrasound examination. The prenatal detection rate varies from condition to 
condition. The overall detection rate for structural anomalies via ultrasound in the first trimester is around 50%,8 
and for lethal anomalies the ultrasound detection rate in the second semester is over 80%.9,10 





Incidence reduced by 
optimal health status before 
and during pregnancy 






Down syndrome and other 
chromosomal disorders 
 x* x 11,12 
Cystic fibrosis    13-15 
Neural tube defects    16 
Cardiovascular anomalies    17-20 
Other structural congenital 
anomalies 
   8-10 
Genetic metabolic disorders  x  21,22 
Congenital hearing loss     23-25 
*incidence is lower in younger women 
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Brief notes relevant to the prevention of congenital anomalies  
Neural tube defects can be prevented by peri-conceptional folic acid supplementation: The Ministry of 
Health recommends that women wishing to become pregnant who are at low risk of having a pregnancy affected 
by a neural tube defect should take 800 µg of folic acid daily for at least four weeks prior to conception and for 
12 weeks after.26 The 2015 Cochrane review on this topic found high quality evidence that daily folic acid 
supplementation prevents neural tube defects (risk ratio 0.31, 95% CI 0.17 to 0.58; five studies; 6708 births).16 
Maternal smoking is associated with an increased risk of non-chromosomal birth defects: Odds ratios in 
the range 1.25–1.50 for limb reduction defects, clubfoot, oral clefts and defects of the eyes and gastrointestinal 
system (especially gastroschisis and abdominal hernias), and odds ratios in the range 1.09–1.19 for digit 
anomalies, cryptorchidism and defects of the heart and musculoskeletal system.27 
Heavy drinking in pregnancy, especially binge drinking, can have severe effects on the developing fetus by 
disrupting brain development leading to cognitive, motor and behavioural disability with life-long 
consequences.28,29 Fetal alcohol syndrome also produces distinctive facial anomalies and growth retardation and 
is associated with a greatly increased risk of vision and hearing impairments, and a wide variety of congenital 
malformations.28,30 
Maternal obesity seems to be associated with a small increase in the rates of some congenital anomalies, 
including heart defects and neural tube defects, and the risk may increase with greater degree of obesity.31-33 In 
addition, maternal obesity is associated with at least 20% lower rates of detection of fetal anomalies via 
ultrasound, in comparison to women with normal body mass index.34,35 
Diabetic women who become pregnant have a risk of having a baby with a major congenital anomaly around 
that is twice that of other women36 and a risk having a baby with a congenital heart defect that is almost four 
times higher.17 These risks can be reduced by optimising maternal health in the peri-conception period 
especially by maintaining good control of blood glucose levels.20 
Maternal infections known to cause birth defects include toxoplasmosis, rubella, cytomegalovirus, herpes, 
and syphilis (the TORCH infections), as well as varicella, influenza, Zika virus and Lymphocytic 
Choriomeningitis (the last two are not known to occur in New Zealand).37-40 
Common medications causing birth defects include: angiotensin converting enzyme inhibitors (for 
hypertension), anticonvulsants (for epilepsy), anti-neoplastic agents (for cancer), and systemic retinoids (for 
acne and other skin conditions).37,41,42 In general, medicines should be prescribed to pregnant women only when 
absolutely necessary, when the benefits outweigh the risks. 
Key points for achieving optimal pre-pregnancy health status to reduce congenital anomaly risk:43 
 Take folic acid supplements (to prevent neural tube defects) 
 Seek medical advice before becoming pregnant if you have a chronic condition such as diabetes, 
hypothyroidism, epilepsy or hypertension where the condition itself, or the medication used to treat it, 
may increase the risk of congenital anomalies in your baby 
 Avoid smoking, alcohol and recreational drugs 
 Lose weight if obese 
 Seek medical advice before becoming pregnant if there is a family history of a genetic disorder 
 Make sure you are immune to rubella, consider varicella vaccination if not already immune 
Key points for achieving optimal health status during pregnancy to reduce congenital anomaly risk43-45 
 Avoid smoking, alcohol and recreational drugs 
 Take folic acid and iodine 
 Do not take therapeutic drugs except on medical advice that the benefits outweigh the risks 
 Register with a Lead Maternity Carer early in pregnancy (before 10 weeks’ gestation) 
 Make a decision about screening tests 
 Take care with personal and food hygiene, wash hands before eating (especially if you have contact 
with young children), and avoid contact with cat faeces 
Although listeria infection does not cause congenital anomalies, pregnant women should avoid eating soft 
cheeses, delicatessen meats, pâtés, hummus-based spreads, refrigerated smoked seafood and salad bar cold 
salads to prevent miscarriage, preterm birth and stillbirth due to listeria infection.46,47 
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The following section uses data from the National Minimum Dataset to describe congenital anomalies in babies 
from 2000–2015 and concludes with a brief overview of some of the evidence relating to early diagnosis of 
these conditions. 
Evidence-based health care for children, young people and parents affected by 
congenital anomalies  
There are many thousands of different congenital anomalies so it is not practical to provide information here on 
the specific care each one requires. Instead, this section offers information on some new developments in 
prenatal and postnatal detection of congenital anomalies and highlights some of the findings from a review of 
the maternity care received by women who experienced perinatal deaths due to congenital anomalies in 
New Zealand in 2010.  
In New Zealand, pregnant women are offered screening tests for Down syndrome and a fetal anatomy scan at 
18–20 weeks’ gestation.48 The aim of fetal anomaly screening is to identify potential problems so that parents 
can make an informed choice about whether to continue the pregnancy if an anomaly is identified and have time 
to prepare for what is to come whether it is a termination, a baby who will need postnatal treatment or palliative 
care, or a child who will have long term disability.49 Prenatal detection also allows planning for delivery in a 
specialist centre and, for a few conditions, intra-uterine therapy.49 Ultrasound scanning to detect fetal 
malformations reduces perinatal mortality rates if there is a high level of diagnostic expertise and termination of 
pregnancy for fetal abnormality is widely accepted in the population.50 
In New Zealand in 2010 there were 211 perinatal deaths due to congenital anomalies (30% of the 704 perinatal 
deaths in that year).51 A review project based on the Perinatal and Maternal Mortality Review Committee 
dataset assessed the quality of the maternity care received by the women with one of the 137 perinatal deaths 
that were due to a congenital cardiovascular, central nervous system or chromosomal abnormality in that year.51 
The review found that first contact with a health practitioner (most often a GP) occurred within 10 weeks of 
gestation in 74% of the women and within 14 weeks in 85% but there was often a significant delay in registering 
with a lead maternity carer (LMC). This meant that some women presented to a LMC too late for first trimester 
screening for Down syndrome. Of the 129 women who presented to a health professional at less than 20 weeks’ 
gestation, 97 (71% of the 137) were offered first and/or second trimester screening and 82 (60% of the 137) had 
first and or second trimester screening. Fifteen women (11% of the 137) declined screening. 
The review also found that only 7% of the women were documented as having taken folate supplements (to 
prevent neural tube defects) prior to pregnancy although 54% had taken them during pregnancy. On review of 
the women’s ultrasound images it was found that some anomalies could have been detected earlier. The review 
made a number of recommendations, including those following. All women should receive preconception 
counselling to optimise their health and identify any risks for congenital anomalies resulting from previous 
obstetric history or family history. There should be a media campaign to promote peri-conceptional folate and 
the evidence on fortification of bread with folate should be further investigated. All women should be educated 
about the importance of booking before 10 weeks. GPs should be effective at offering first trimester screening 
since they are often a woman’s first point of contact with maternity care and they should expedite booking with 
a LMC. If screening has not already been arranged then LMCs should offer all women first and second trimester 
screening, as required by the Ministry of Health, as this will enable the early diagnosis of a proportion of 
congenital anomalies. 
It is now possible to test for Down, Edwards and Patau syndromes early in pregnancy using cell-free fetal DNA 
obtained from a sample of the mother’s blood (non-invasive prenatal testing, NPIT).52 A recent systematic 
review commissioned by the UK National Screening Committee, which included 41 studies relevant to Down 
syndrome, found that NPIT has very high sensitivity (99.3%) and specificity (99.9%) for Down syndrome.53 
Nevertheless, in the general obstetric population where the prevalence of Down syndrome is low, it could be 
expected that for every four Down syndrome cases detected there would be one false positive result so it is 
essential that, if a woman is considering a termination following a positive NPIT result, she has the diagnosis 
confirmed with an invasive diagnostic test (amniocentesis or chorionic villus sampling).53 Non-invasive prenatal 
testing is available to New Zealand women on a user pays basis but is not part of publically funded ante-natal 
screening.54 
Congenital heart disease (CHD) causes more early neonatal deaths that any other type of congenital anomaly, 
accounting for around 30% of all early neonatal deaths associated with congenital anomalies in EUROCAT (a 
European network of population-based registries) in 2008–2012.55 In cases of major or critical CHD (defined as 
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cases requiring intervention or resulting in death within one year or within four weeks, respectively) delayed 
diagnosis is associated with increased mortality and morbidity.56 
In New Zealand during 2006–2010 antenatal ultrasound picked up only 46% of critical CHD.57 Postnatal 
physical examination cannot detect all babies with CHD as some do not display any physical symptoms until 
after hospital discharge.56 Almost 20% of New Zealand infants with critical CHD are not diagnosed until after 
initial hospital discharge.57 
Newborn pulse oximetry will detect hypoxaemic infants and is a simple and non-invasive method for screening 
for CHD which increases detection rates for CHD when used as an adjunct to physical examination.56 A number 
of developed countries have such screening and a pulse oximetry pilot programme is currently underway in 
Auckland.58,59 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of congenital anomalies are provided for further reading. 
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screening-down-syndrome-and-other-conditions-guidelines-health-practitioners  
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Cystic fibrosis (CF) is a multi-organ disease with an autosomal recessive pattern of inheritance. For a child to 
have CF both parents need to be carriers of a CF gene. It is most common in populations of predominantly 
Northern European descent where around one in 3,000 babies are born with the condition.1 Most developed 
countries where CF is common, including New Zealand, have national newborn screening programmes that 
identify most babies with CF soon after birth.1,2  
Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein.3 The CFTR regulates anion transport across cell membranes. When CFTR activity is 
reduced or absent the mucus secreting functions of the epithelial cells lining the airways, pancreatic ducts and 
other tissues are impaired.3 The most significant result of this dysfunction is obstruction of the small airways by 
thick mucus leading to frequent infections, bronchiectasis and progressively worsening lung function. Other 
effects include pancreatic insufficiency leading to malabsorption of nutrients (and diabetes in some cases), and 
cirrhosis of the liver. Most males with CF have congenital absence of the vas deferens which makes them 
infertile.4  
Life expectancy for people with CF is improving due to better treatment and it is now around forty years.1,5 
Recently, new drugs have been developed that correct the basic defect in CFTR function.6 These drugs hold the 
promise of effective disease-modifying treatment and could potentially prevent lung disease if they were started 
as soon as the disease was identified by newborn screening.1 
The following section reviews cystic fibrosis in children and young people using information from the newborn 
metabolic screening programme, New Zealand Cystic Fibrosis Registry, National Mortality Collection and 
National Minimum Dataset. The section concludes with a brief overview of possibilities for prevention and 
evidence-based health care for children and young people with CF. 
Data sources and methods 
Indicator  
 Rates of cystic fibrosis (CF) among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with cystic fibrosis per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Cystic fibrosis was the principal diagnosis or was documented as one of the first 15 diagnoses  
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
There was a total of 14 deaths of 0–24 year olds with cystic fibrosis (CF) as the underlying cause of death in 
New Zealand during 2009 to 2013, as documented within the National Mortality Collection. 
CF is one of the 20 congenital metabolic disorders that babies are screened for within the New Zealand 
Newborn Metabolic Screening Programme (NMSP).2 Screening tests are performed utilising blood samples 
obtained from the babies’ heels during the first 48–72 hours of life. The NMSP screened 58,673 babies in 2014, 
of which 15 had cystic fibrosis detected. The 2014 incidence rate of CF was 27.1 per 100,000 live births, 
including one case diagnosed outside of the NMSP. 
The National Cystic Fibrosis Data Registry includes over 95% of people with CF in New Zealand. Around two-
thirds (n=293) of the 443 individuals registered in 2014 were registered before 24 years. Of those registered, 33 
(7.4%) were aged 0–3 years at registration.7  
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The number of 0–24 year olds hospitalised with CF during 2011 to 2015 is presented in Table 18. It also 
presents the number of hospital discharges in which CF was documented as the primary diagnosis or as any 
diagnosis. 
While there has been year-on-year variability in hospitalisations for CF since 2000, the hospitalisation rate has 
remained relatively stable over the last five years (Figure 8). 
Table 18. Individuals aged 0–24 years hospitalised with cystic fibrosis using primary diagnosis compared to all 
cases, New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary  
Primary diagnosis All cases 
Cystic fibrosis 
Hospitalisation 
0–24 years 336 2,122 2,625 1.24 
0–14 years 226 1,199 1,533 1.28 
15–24 years 147 923 1,092 1.18 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with cystic fibrosis listed in any of the first 15 
diagnoses; The sum of the age groups may total to more than the 0–24 year old total 
Figure 8. Hospitalisations for cystic fibrosis in 0–24 year olds, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with cystic fibrosis listed in any of the first 15 diagnoses 
Diagnosis  
The majority of hospitalisations of 0–24 year olds involving cystic fibrosis had CF as the primary reason for 
hospitalisation. The diagnoses with the highest hospitalisation rate were CF with pulmonary or other 
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Table 19. Hospitalisations involving cystic fibrosis in 0–24 year olds, by primary diagnosis, New Zealand 
2011– 2015 
Primary diagnosis n 
Annual 
average 
Rate 95% CI % 
Cystic fibrosis* in 0–24 year olds 
New Zealand  
Cystic fibrosis with pulmonary manifestations 955 191 12.43 11.67–13.25 36.4 
Cystic fibrosis with intestinal manifestations 76 15 0.99 0.79–1.24 2.9 
Cystic fibrosis with other manifestations 968 194 12.60 11.83–13.42 36.9 
Cystic fibrosis, unspecified 123 25 1.60 1.34–1.91 4.7 
Cystic fibrosis total 2,122 424 27.63 26.48–28.83 80.8 
Other endocrine, nutritional and metabolic diseases 12 2 0.16 0.09–0.27 0.5 
Diseases of the respiratory system 106 21 1.38 1.14–1.67 4.0 
Diseases of the musculoskeletal system and connective tissue 76 15 0.99 0.79–1.24 2.9 
Factors influencing health service contact 75 15 0.98 0.78–1.22 2.9 
Symptoms and/or abnormal clinical findings NEC 69 14 0.90 0.71–1.14 2.6 
Injury and/or poisoning 58 12 0.76 0.58–0.98 2.2 
Infectious and parasitic diseases 38 8 0.49 0.36–0.68 1.4 
Other diagnoses 69 14 0.90 0.71–1.14 2.6 
Total 2,625 525 34.18 32.89–35.51 100.0 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Cystic fibrosis in any of the 
first 15 diagnoses; Rate per 100,000 0–24 year olds; NEC = not elsewhere classified  
Demographic distribution 
Table 20 presents the demographic distribution of individuals with CF in New Zealand between 2011 and 2015. 
CF was significantly lower among individuals residing in areas with high deprivation scores (NZDep2013 
deciles 9–10), and significantly higher among 0–4 year olds compared to 15–24 year olds. The majority of 
individuals with CF were of European/Other ethnicities.  
Although the age specific rate of 0–4 year olds with CF is higher than those for the other age groups, 
hospitalisations have generally been lower for 0–4 year olds (Figure 9). The hospitalisation rate for Māori has 
gradually increased since 2000, although is still consistently lower than the hospitalisation rate for 
European/Other (Figure 10). 
Figure 9. Hospitalisations for cystic fibrosis in 0–24 year olds, by age group, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 















































































































































































Rate per 100,000 
population 
Rate ratio 95% CI 
Cystic fibrosis* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 97 6.84 1.00   
Deciles 3–4 105 7.85 1.15 0.87–1.51 
Deciles 5–6 100 6.94 1.01 0.77–1.34 
Deciles 7–8 97 5.97 0.87 0.66–1.16 
Deciles 9–10 74 3.98 0.58 0.43–0.79 
Prioritised ethnicity 
Māori 38 2.11 0.30 0.22–0.43 
Pacific 5 0.71 0.10 0.04–0.25 
Asian/Indian 6 0.63 0.09 0.04–0.20 
MELAA 5 4.96 0.71 0.30–1.73 
European/Other 285 6.94 1.00   
Gender 
Female 154 4.10 1.00   
Male 183 4.66 1.14 0.92–1.41 
Age group (years) 
0–4 106 6.80 1.45 1.13–1.86 
5–14 153 5.13 1.09 0.87–1.37 
15–24 147 4.69 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. Cystic fibrosis* in any of the 
first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is Level 1 prioritised; Decile is 
NZDep2013 
Figure 10. Hospitalisations involving cystic fibrosis in 0–24 year olds, by ethnicity, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with cystic fibrosis listed in any of the first 15 diagnoses 
Regional trends and distribution 
Table 21 presents the number of individuals resident in each district health board that had a CF diagnosis during 
2011 to 2015. It also presents the number of hospital discharges in which CF was documented as the primary 
















































































































































































The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with CF occur 
when this condition is not the primary diagnosis and it provides and indication of the extent to which using only 
the primary diagnosis undercounts CF related hospitalisations. A high ratio may be associated with more 
thorough documentation and it may also indicate that children with CF are often hospitalised for other 
conditions (Table 21). 
While there was year-on-year variability in the hospitalisation rate for CF within Southern DHB and its regions, 
the hospitalisation rate had generally decreased since 2000 for Southern DHB (Figure 11). 
Table 21. Hospitalisations for cystic fibrosis in 0–24 year olds, Southern DHB vs New Zealand 2011–2015 
DHB/area Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Principal diagnosis All cases 
Cystic fibrosis in 0–24 year olds 
Southern 27 167 200 1.20 
Otago 19 128 149 1.16 
Southland 9 39 51 1.31 
New Zealand 336 2,122 2,625 1.24 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with cystic fibrosis listed in any of the first 15 
diagnoses 
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All cases
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with cystic fibrosis listed in any of the first 15 diagnoses 
Evidence for good practice 
Possibilities for prevention 
Preconception carrier screening of couples planning a pregnancy and prenatal testing early in pregnancy are 
both possible and recommended by the American College of Medical Genetics,8 the American College of 
Obstetricians and Gynecologists,9 the National Institutes of Health,10 and the Human Genetics Society of 
Australasia.11 The sensitivity of carrier screening varies between ethnic groups and ranges (in the US 
population) from almost 90% in non-Hispanic whites to around 50% in Asian Americans.9 In places where 
carrier screening has been carried out, there has been a decrease in the incidence of cystic fibrosis.12,13 
In New Zealand, carrier screening and prenatal testing is free only for family members and partners of people 
with CF and relatives and partners of known carriers of CF.11,14 In Australia, since 2006, CF carrier screening 
has been available to individuals and couples in Victoria as a fee-for-service programme at a cost of $150 per 
patient.15 There has been some resistance to the uptake of CF screening from both the public (who lack 
awareness of CF) and health professionals. Some health professionals have concerns about the time needed to 
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counsel patients about genetic testing, lack knowledge about carrier frequency and the risks of CF and are 
unaware that 95% of cases of CF occur without a family history of the condition.15 
It is difficult to assess the cost-effectiveness of carrier screening and published economic evaluations of CF 
screening have had considerable variation in methods and results.16 Estimating cost-effectiveness involves 
weighing the cost of screening against the cost savings that result from the lifetime healthcare costs averted 
because there are fewer people with CF (because couples who are both carriers can choose to terminate their 
affected foetuses or to use IVF with preimplantation genetic testing). There are new developments in genetic 
testing, including next-generation DNA sequencing, that make it possible to screen for many disorders at once 
and are likely to bring down the cost of genetic testing.17 Therapies for CF are advancing and it is possible that 
in the future there may be treatments that can be given from birth to correct the defect in CFTR function and 
prevent some or all of the complications of CF.18 The availability of such therapies could have several 
consequences: people with CF would be more likely to live longer with a good quality of life (although new 
drugs will probably be very expensive), and couples might be less likely to terminate a CF pregnancy if they 
were more hopeful of their child’s prognosis, (providing they did not have to pay for their child’s healthcare 
themselves).18 
Evidence-based health care for children and young people with cystic fibrosis 
Newborn screening leads to better nutritional outcomes for children with CF and has the potential to improve 
pulmonary outcomes.19 When a couple have a baby with CF, there is a risk that any future pregnancies may also 
be affected by CF, so genetic counselling is indicated. The international consensus is that a person newly 
diagnosed with CF should have immediate and on-going access to a CF specialist centre staffed by a 
multidisciplinary team.20 New Zealand does not have the population to support the types of specialist CF centres 
found overseas. Care for New Zealand children with CF should be provided using a shared care model. The 
majority of care should be based in a clinic at a hospital near their home, supplemented with at least annual 
reviews at a regional CF centre.21 
To maintain the best possible lung function, people with CF (PWCF) need meticulous daily management of 
their lung disease. This may involve the use of airway clearance techniques taught by physiotherapists and 
inhaled aerosol medications together with prompt and aggressive treatment of infective exacerbations.20 There is 
no good evidence to indicate which is the best way of educating PWCF to manage their disease.22 People with 
CF need monitoring of their nutritional status as they are at risk of CF-related malnutrition due to pancreatic 
insufficiency and they (and their families) need psychosocial support to deal with the demoralisation that results 
from having multiple health problems.20 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of CF are provided for further reading. 
New Zealand guidelines 
 Standards of Care for Cystic Fibrosis in New Zealand Group, Medical Advisory Committee of Cystic 
Fibrosis Association of New Zealand. 2011. Standards of Care for Cystic Fibrosis in New Zealand Cystic 
Fibrosis Association of New Zealand.  
http://www.cfnz.org.nz/wp-content/uploads/Standard-of-Care-NZ-2011.pdf 
International guidelines 
 Lahiri T, Hempstead SE, Brady C, et al. 2016. Clinical Practice Guidelines from the Cystic Fibrosis 
Foundation for preschoolers with cystic fibrosis. Pediatrics. 
http://pediatrics.aappublications.org/content/137/4/e20151784.long 
 Smyth AR, Bell SC, Bojcin S, et al. 2014. European Cystic Fibrosis Society Standards of Care: Best 
Practice guidelines. Journal of Cystic Fibrosis, 13 Suppl 1, S23–42. 
http://www.sciencedirect.com/science/article/pii/S156919931400085X 
 Conway S, Balfour-Lynn IM, De Rijcke K, et al. 2014. European Cystic Fibrosis Society Standards of 
Care: Framework for the Cystic Fibrosis Centre. Journal of Cystic Fibrosis, 13, S3-S22. 
http://www.sciencedirect.com/science/article/pii/S1569199314000848 
 Stern M, Bertrand DP, Bignamini E, et al. 2014. European Cystic Fibrosis Society Standards of Care: 
Quality management in cystic fibrosis. Journal of Cystic Fibrosis, 13, Supplement 1, S43-S59. 
http://www.sciencedirect.com/science/article/pii/S1569199314000861 
 Cystic Fibrosis Trust. 2011. Standards for the clinical care of children and adults with cystic fibrosis in the 





Evidence-based medicine reviews 
 The Cochrane Library Reviews relating to Cystic Fibrosis 
http://www.cochranelibrary.com/topic/Lungs%20%26%20airways/Fibrosis%3A%20cystic%20fibrosis/?per
-page=100&stage=review  
 Edmondson C, Davies JC. 2016. Current and future treatment options for cystic fibrosis lung disease: latest 
evidence and clinical implications. Therapeutic Advances in Chronic Disease, 7(3), 170-83. 
http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27347364/ 
 Saiman L, Siegel JD, LiPuma JJ, et al. 2014. Infection prevention and control guideline for cystic fibrosis: 
2013 update. Infection Control & Hospital Epidemiology, 35 Suppl 1, S1-S67.  
(summary at http://www.guideline.gov/content.aspx?id=48772&search=cystic+fibrosis)  
 Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al. 2013. Cystic fibrosis pulmonary guidelines. Chronic 
medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine, 
187(7), 680-9. (summary at https://www.guideline.gov/content.aspx?id=45307) 
Other relevant publications 
 Quon BS, Rowe SM. 2016. New and emerging targeted therapies for cystic fibrosis. BMJ, 352, i859. 
http://www.bmj.com/content/352/bmj.i859.long 
 Massie J, Ioannou L, Delatycki M. 2014. Prenatal and preconception population carrier screening for cystic 
fibrosis in Australia: where are we up to? The Australian & New Zealand Journal of Obstetrics & 
Gynaecology, 54(6), 503-9 
 PORT CFNZ National Data Registry. 2014 Registry Report. Cystic Fibrosis New Zealand. 
http://cfnz.org.nz/wp-content/uploads/2015/12/2014-PORT-CFNZ-Registry-Report.pdf 
Websites 
 National Institute for Health and Care Excellence Cystic Fibrosis 
https://www.nice.org.uk/guidance/conditions-and-diseases/genetic-conditions/cystic-fibrosis 
 Cystic Fibrosis Association Of New Zealand Publications http://www.cfnz.org.nz/our-
services/library/downloads/ 
 Cystic Fibrosis Trust (UK) Consensus Documents https://www.cysticfibrosis.org.uk/the-work-we-
do/clinical-care/consensus-documents 
 European Cystic Fibrosis Society Standards of care available in open access 
https://www.ecfs.eu/content/ecfs-standards-care-available-open-access 
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